Start with the fact that makes the whole reform make sense, because without it the changes look like the state going soft on infant drug exposure, and that is not what is happening.

The rapid urine drug tests hospitals routinely use on birthing patients are cheap, fast, and, per a joint investigation by The Marshall Project and Reveal, carry false positive rates as high as 50%. Common foods and medications set them off. New Jersey's own attorney general documented cases where hospitals reported two different women to child protective services over positives caused by bagels with poppy seeds. Morphine given during childbirth, legal CBD products, and prescribed medications can all produce a "positive" that reflects nothing about parental fitness.

That is the engine of the problem New Jersey is trying to fix. A screening test designed to be over-inclusive, meant to flag anything worth a second look, was being treated as proof, and that proof was triggering some of the most invasive state action a family can face.

What actually happened to families

To understand why this rose to the level of a civil-rights lawsuit and a statewide policy change, you have to see the consequences of a false positive, because they were severe and they fell on people who had done nothing wrong.

New parents flagged by these tests were subjected to intense scrutiny: unannounced home visits, interviews, and the constant fear that their newborn could be taken. In one case cited in litigation, a mother alleged she was not allowed to touch or hold her baby, and the state took custody of the newborn for seven months, despite no court ever finding she lacked parental capacity. Another mother described spending the first weeks of her newborn's life in a panic after a hospital test flagged opiates; months of investigation, including a search of her home and interviews with her family, ended with the agency finding no evidence of abuse, neglect, or drug use at all.

These are not stories of dangerous parents caught in time. They are stories of a screening tool's known error rate colliding with a mandatory-reporting system that treated the screen as conclusive. The harm was real, it was documented, and it is what the reform is responding to.

The New Jersey specifics: this state was already an outlier in the law

New Jersey is a revealing place for this fight, because its own highest court had already said, years ago, that a positive test should not carry the weight hospitals were giving it.

Back in 2013, the New Jersey Supreme Court ruled that drug use during pregnancy cannot be prosecuted under child-abuse laws and that a positive drug test, by itself, does not establish neglect. New Jersey also does not criminalize substance use during pregnancy, unlike some states. So there was already a legal principle on the books that a test result alone proves nothing about whether a child is at risk. The practice on hospital maternity floors had simply drifted away from that principle, with universal testing and automatic reporting doing the opposite of what the court had instructed.

The gap between the law and the practice is what the attorney general targeted. In 2024, New Jersey filed a civil-rights suit against the hospital network Virtua Health, alleging it drug-tested every birthing patient without informed consent and reported every positive, no matter the cause. The state's framing was pointed: singling out pregnant patients for mandatory testing that no other category of hospital patient faced was itself a form of discrimination. The numbers underscored it. Virtua accounted for about 9.4% of the state's delivery hospitalizations in 2022 but nearly a quarter of all such reports filed to child protection.

What the reform actually changes

The state's response, reflected in Health Department guidance to hospitals and birth centers, is not a ban on testing. It is a set of corrections aimed precisely at the failure points above, and understanding each one shows the logic.

First, and most fundamental, the guidance states plainly that a positive screening test is not, by itself, evidence of child abuse under New Jersey law, restating the 2013 court principle that practice had abandoned. Second, it directs that follow-up biologic testing should only be undertaken with the patient's informed consent, closing the consent gap the lawsuit centered on. Third, it reframes universal screening as a health-equity tool, meaning a conversation about risk and support offered to everyone, rather than a punitive dragnet, and it emphasizes informing patients and offering them a role in any reporting, including the option to connect with treatment and build a care plan before birth.

The throughline is a shift from a punitive default to a public-health default. Instead of "test, and a positive automatically triggers the child-welfare machinery," the model becomes "screen with consent, treat a positive as one data point requiring context, and route families toward support rather than investigation."

The genuinely hard part, which the reform does not erase

It would be dishonest to present this as a simple story of good reform fixing bad policy, because the underlying tension is real and the reform does not make it disappear.

Substance exposure in newborns is a genuine danger. The hospital at the center of the New Jersey suit adopted universal testing in 2018 after staff reported seeing more newborns with opioid-withdrawal symptoms, which is a real clinical concern, not a pretext. Opioid-affected infants exist, they can be seriously harmed, and a system that swings too far toward protecting parental privacy could miss a child who needed intervention. Federal law under CAPTA also requires states to have a protocol for identifying substance-affected infants, so New Jersey cannot simply stop looking.

The honest framing is that this is a calibration problem, not a binary. The old system was calibrated to catch every possible case at the cost of harming many innocent families and disproportionately, since investigations of drug use in pregnancy are, as the medical literature notes, strongly biased against racial and ethnic minorities even where usage rates are similar. The reform recalibrates toward accuracy and consent. But it still has to catch the genuinely at-risk infant, and whether it strikes that balance correctly is something that will only be visible in how it plays out. A reform that over-corrects carries its own risk, to a different, smaller, but real group of children.

The piece the states can't fix alone

There is one part of this that New Jersey cannot solve on its own, and it is worth naming because it explains why the problem is national.

The reason a "positive" is so unreliable in the first place is that the cutoff thresholds labs use, the level at which a result flips from negative to positive, are largely discretionary and vary widely. One reporting analysis found child-welfare testing thresholds so low that, by federal workplace standards, the same sample would read negative, an Air Force pilot could fly with far more of a substance in their system than triggered a child-welfare case. There is no national consensus on what the levels should be, and the federal expert panel that had been working on scientifically valid standards was disbanded. So a mother's fate can turn on which lab her hospital happened to use and what cutoff that lab happened to choose.

New Jersey can require consent and demand context around a positive. It cannot, by itself, fix the fact that "positive" means different things in different labs. Until there is a shared, evidence-based standard for what these tests should measure and report, states are reforming around the edges of a measurement problem they did not create and cannot fully resolve.

What it comes down to

New Jersey's overhaul is a serious attempt to fix a documented harm: a screening tool with a high error rate was being used as if it were proof, and families paid for the gap with investigations, home searches, and, in the worst cases, separation from their newborns. Requiring consent, restating that a screen is not evidence of abuse, and steering families toward support rather than surveillance are rational responses to that record.

The reform is not a declaration that infant drug exposure does not matter. It is a bet that a system built on accurate testing, informed consent, and public-health support will protect more children than a system built on over-inclusive tests and automatic reporting, while sparing the many innocent families the old approach swept up.

The tests were never as certain as the word "positive" made them sound, and a lot of families were harmed by pretending otherwise.

Further reading